Clinical Trials Directory

Trials / Unknown

UnknownNCT04895176

incidenCe and predictOrs of heaRt fAiLure After Acute coronarY Syndrome: CORALYS

Status
Unknown
Phase
Study type
Observational
Enrollment
10,000 (estimated)
Sponsor
A.O.U. Città della Salute e della Scienza · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Single-cohort retrospective study evaluating the incidence and prognostic markers of heart failure following acute coronary syndrome treated by percutaneous coronary intervention

Detailed description

Acute coronary syndrome (ACS) is the most common cause of heart failure (HF) world-wide. Primary percutaneous coronary intervention (PCI) has deeply improved short and long-term survival after ACS, but his impact on incidence of downstream heart failure still remains unclear and heart failure after ACS represents the major driver of late morbidity, mortality and healthcare cost. Many predictors and determinant of heart failure after MI have been evaluated, however, to date, the optimal combination of parameters to predict heart failure after MI needs to be defined and very little is known about the prognostic markers in unstable angina setting The aim of this retrospective study: * to show the incidence of heart failure after acute coronary artery syndrome, and the relation between the type of ACS and following incidence of HF. * to clarify which features could be routinely identified as prognostic markers. This study is a multi-center non-randomized, single-cohort retrospective study including consecutive patients with acute coronary syndrome treated by percutaneous coronary intervention between 2017 and 2019, without known previous heart failure (baseline EF \> 40% and no medical therapy with loop diuretics), with at least 12 months of follow-up. It is possible to anticipate that the main findings of the present study will fill fundamental knowledge gaps regarding incidence of heart failure following coronary events. Among this, the study could suggest specific clinical and epidemiological features related to the risk of development of HF, leading to a better medical treatment and reducing risk for further hospitalizations.

Conditions

Timeline

Start date
2021-06-01
Primary completion
2021-06-30
Completion
2021-06-30
First posted
2021-05-20
Last updated
2021-05-20

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT04895176. Inclusion in this directory is not an endorsement.